D. Corpet and S. Tache, Most Effective Colon Cancer Chemopreventive Agents in Rats: A Systematic Review of Aberrant Crypt Foci and Tumor Data, Ranked by Potency, Nutrition and Cancer, vol.43, issue.1, pp.1-421, 2002.
DOI : 10.1207/S15327914NC431_1

URL : https://hal.archives-ouvertes.fr/hal-00284366

B. Buecher, M. Heymann, and H. Blottiere, Rationale and prospects for the use of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer, Gastroenterol Clin Biol, vol.25, pp.967-978, 2001.

L. Rosenberg, J. Palmer, A. Zauber, M. Warshauer, P. Stolley et al., A Hypothesis: Nonsteroidal Anti-Inflammatory Drugs Reduce the Incidence of Large-Bowel Cancer, JNCI Journal of the National Cancer Institute, vol.83, issue.5, pp.355-358, 1991.
DOI : 10.1093/jnci/83.5.355

R. Dubois, F. Giardiello, and W. Smalley, NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, EICOSANOIDS, AND COLORECTAL CANCER PREVENTION, Gastroenterology Clinics of North America, vol.25, issue.4, pp.773-791, 1996.
DOI : 10.1016/S0889-8553(05)70274-0

R. Sandler, J. Galanko, S. Murray, J. Helm, and J. Woosley, Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas, Gastroenterology, vol.114, issue.3, pp.441-447, 1998.
DOI : 10.1016/S0016-5085(98)70526-8

R. Dubois, S. Abramson, L. Crofford, R. Gupta, L. Simon et al., Cyclooxygenase in biology and disease, FASEB J, vol.12, pp.1063-1073, 1998.

W. Smith and R. Langenbach, Why there are two cyclooxygenase isozymes, Journal of Clinical Investigation, vol.107, issue.12, pp.1491-1495, 2001.
DOI : 10.1172/JCI13271

W. Smith, D. Dewitt, and R. Garavito, Cyclooxygenases: Structural, Cellular, and Molecular Biology, Annual Review of Biochemistry, vol.69, issue.1, pp.145-182, 2000.
DOI : 10.1146/annurev.biochem.69.1.145

C. Eberhart, R. Coffey, A. Radhika, F. Giardiello, S. Ferrenbach et al., Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas, Gastroenterology, vol.107, issue.4, pp.1183-1188, 1994.
DOI : 10.1016/0016-5085(94)90246-1

H. Sano, Y. Kawahito, R. Wilder, A. Hashiramoto, S. Mukai et al., Expression of cyclooxygenase-1 and -2 in human colorectal cancer, Cancer Res, vol.55, pp.3785-3789, 1995.

W. Karnes, . Jr, R. Shattuck-brandt, L. Burgart, R. Dubois et al., Reduced COX-2 protein in colorectal cancer with defective mismatch repair, Cancer Res, vol.58, pp.5473-5477, 1998.

J. Shao, H. Sheng, R. Aramandla, M. Pereira, R. Lubet et al., Coordinate regulation of cyclooxygenase-2 and TGF-1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors, Carcinogenesis, vol.20, issue.2, pp.185-191, 1999.
DOI : 10.1093/carcin/20.2.185

S. Boolbol, A. Dannenberg, A. Chadburn, C. Martucci, X. Guo et al., Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis, Cancer Res, vol.56, pp.2556-2560, 1996.

B. Rigas, I. Goldman, and L. Levine, Altered eicosanoid levels in human colon cancer, J Lab Clin Med, vol.122, pp.518-523, 1993.

M. Tsujii and R. Dubois, Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2, Cell, vol.83, issue.3, pp.493-501, 1995.
DOI : 10.1016/0092-8674(95)90127-2

C. Liu, S. Chang, K. Narko, O. Trifan, M. Wu et al., Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice, Journal of Biological Chemistry, vol.276, issue.21, pp.18563-18569, 2001.
DOI : 10.1074/jbc.M010787200

T. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J. Mitchell et al., Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis, Proceedings of the National Academy of Sciences, vol.33, issue.5753, pp.7563-7568, 1999.
DOI : 10.1038/284271a0

H. Debinski, J. Trojan, K. Nugent, A. Spigelman, and R. Phillips, Effect of sulindac on small polyps in familial adenomatous polyposis, The Lancet, vol.345, issue.8953, pp.855-856, 1995.
DOI : 10.1016/S0140-6736(95)92989-4

G. Steinbach, P. Lynch, R. Phillips, M. Wallace, E. Hawk et al., The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis, New England Journal of Medicine, vol.342, issue.26, pp.1946-1952, 2000.
DOI : 10.1056/NEJM200006293422603

R. Phillips, M. Wallace, P. Lynch, E. Hawk, G. Gordon et al., A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis, Gut, vol.50, issue.6, pp.857-860, 2002.
DOI : 10.1136/gut.50.6.857

M. Cruz-correa, L. Hylind, K. Romans, S. Booker, and F. Giardiello, Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study, Gastroenterology, vol.122, issue.3, pp.641-645, 2002.
DOI : 10.1053/gast.2002.31890

B. Reddy, C. Rao, and K. Seibert, Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis, Cancer Res, vol.56, pp.4566-4569, 1996.

T. Kawamori, C. Rao, K. Seibert, and B. Reddy, Chemopreventive activity of celecoxib, a 354 B. Buecher et al. specific cyclooxygenase-2 inhibitor, against colon carcinogenesis, Cancer Res, vol.58, pp.409-412, 1998.

R. Sandler, EPIDEMIOLOGY AND RISK FACTORS FOR COLORECTAL CANCER, Gastroenterology Clinics of North America, vol.25, issue.4, pp.717-735, 1996.
DOI : 10.1016/S0889-8553(05)70271-5

D. Burkitt, Possible relationships between bowel cancer and dietary habits, Proc R Soc Med, vol.64, pp.964-965, 1971.

C. Fuchs, E. Giovannucci, G. Colditz, D. Hunter, M. Stampfer et al., Dietary Fiber and the Risk of Colorectal Cancer and Adenoma in Women, New England Journal of Medicine, vol.340, issue.3, pp.169-176, 1999.
DOI : 10.1056/NEJM199901213400301

D. Alberts, M. Martinez, D. Roe, J. Guillen-rodriguez, J. Marshall et al., Lack of Effect of a High-Fiber Cereal Supplement on the Recurrence of Colorectal Adenomas, New England Journal of Medicine, vol.342, issue.16, pp.1156-1162, 2000.
DOI : 10.1056/NEJM200004203421602

C. Bonithon-kopp, O. Kronborg, A. Giacosa, U. Rath, and J. Faivre, Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial, The Lancet, vol.356, issue.9238, pp.1300-1306, 2000.
DOI : 10.1016/S0140-6736(00)02813-0

A. Schatzkin, E. Lanza, D. Corle, P. Lance, F. Iber et al., Lack of Effect of a Low-Fat, High-Fiber Diet on the Recurrence of Colorectal Adenomas, New England Journal of Medicine, vol.342, issue.16, pp.1149-1155, 2000.
DOI : 10.1056/NEJM200004203421601

S. Bingham, N. Day, R. Luben, P. Ferrari, N. Slimani et al., Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study, Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study, pp.1496-1501, 2003.
DOI : 10.1016/S0140-6736(03)13174-1

URL : https://hal.archives-ouvertes.fr/inserm-00110132

U. Peters, R. Sinha, N. Chatterjee, A. Subar, R. Ziegler et al., Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme, The Lancet, vol.361, issue.9368, pp.1491-1495, 2003.
DOI : 10.1016/S0140-6736(03)13173-X

S. Siavoshian, J. Segain, M. Kornprobst, C. Bonnet, C. Cherbut et al., Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression, Gut, vol.46, issue.4, pp.507-514, 2000.
DOI : 10.1136/gut.46.4.507

L. Augenlicht, J. Mariadason, A. Wilson, D. Arango, W. Yang et al., Short chain fatty acids and colon cancer, J Nutr, vol.132, pp.3804-3808, 2002.

H. Blottière, B. Buecher, J. Galmiche, and C. Cherbut, Molecular analysis of the effect of short-chain fatty acids on intestinal cell proliferation, Proceedings of the Nutrition Society, vol.9, issue.01, pp.101-106, 2003.
DOI : 10.1128/MCB.20.5.1797-1815.2000

S. Siavoshian, H. Blottière, L. Foll, E. Kaeffer, B. Cherbut et al., COMPARISON OF THE EFFECT OF DIFFERENT SHORT CHAIN FATTY ACIDS ON THE GROWTH AND DIFFERENTIATION OF HUMAN COLONIC CARCINOMA CELL LINESIN VITRO, Cell Biology International, vol.21, issue.5, pp.281-287, 1997.
DOI : 10.1006/cbir.1997.0153

J. Segain, D. Raingeard-de-la-bletiere, A. Bourreille, V. Leray, N. Gervois et al., Butyrate inhibits inflammatory responses through NFkappa B inhibition: implications for Crohn's disease, Gut, vol.47, issue.3, pp.397-403, 2000.
DOI : 10.1136/gut.47.3.397

A. Mcintyre, P. Gibson, and G. Young, Butyrate production from dietary fibre and protection against large bowel cancer in a rat model., Gut, vol.34, issue.3, pp.386-391, 1993.
DOI : 10.1136/gut.34.3.386

P. Perrin, F. Pierre, Y. Patry, M. Champ, M. Berreur et al., Only fibres promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats, Gut, vol.48, issue.1, pp.53-61, 2001.
DOI : 10.1136/gut.48.1.53

R. Bird, Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings, Cancer Letters, vol.37, issue.2, pp.147-151, 1987.
DOI : 10.1016/0304-3835(87)90157-1

T. Pretlow, O. Riordan, M. Somich, G. Amini, S. Pretlow et al., Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate, Carcinogenesis, vol.13, issue.9, pp.1509-1512, 1992.
DOI : 10.1093/carcin/13.9.1509

G. Caderni, A. Giannini, L. Lancioni, C. Luceri, A. Biggeri et al., Characterisation of aberrant crypt foci in carcinogen-treated rats: association with intestinal carcinogenesis, British Journal of Cancer, vol.71, issue.4, pp.763-769, 1995.
DOI : 10.1038/bjc.1995.148

R. Gupta and R. Dubois, Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2, Nature Reviews Cancer, vol.1, issue.1, pp.11-21, 2001.
DOI : 10.1038/35094017

Y. Yamada, N. Yoshimi, Y. Hirose, A. Hara, M. Shimizu et al., Suppression of Occurrence and Advancement of ??-Catenin-accumulated Crypts, Possible Premalignant Lesions of Colon Cancer, by Selective Cyclooxygenase-2 Inhibitor, Celecoxib, Japanese Journal of Cancer Research, vol.109, issue.6, pp.617-623, 2001.
DOI : 10.1111/j.1349-7006.2001.tb01139.x

B. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff et al., Chemoprevention of colon cancer by specific cyclo- oxygenase-2 inhibitor

W. Brown, S. Skinner, C. Malcontenti-wilson, A. Misajon, T. Dejong et al., Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model, Journal of Gastroenterology and Hepatology, vol.52, issue.12, pp.1386-1392, 2000.
DOI : 10.1046/j.1440-1746.2000.02370.x

D. Topping and P. Clifton, Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides, Physiol Rev, vol.81, pp.1031-1064, 2001.

L. Blay, G. Michel, C. Blottière, H. Cherbut, and C. , Prolonged intake of fructo-oligosaccharides induces a short-term elevation of lactic acid-producing bacteria and a persistent increase in cecal butyrate in rats, J Nutr, vol.129, pp.2231-2235, 1999.

B. Reddy, R. Hamid, and C. Rao, Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition, Carcinogenesis, vol.18, issue.7, pp.1371-1374, 1997.
DOI : 10.1093/carcin/18.7.1371

M. Wijnands, M. Appel, V. Hollanders, and R. Woutersen, A comparison of the effects of dietary cellulose and fermentable galacto-oligosaccharide, in a rat model of colorectal carcinogenesis: fermentable fibre confers greater protection than non-fermentable fibre in both high and low fat backgrounds, Carcinogenesis, vol.20, issue.4, pp.651-656, 1999.
DOI : 10.1093/carcin/20.4.651

S. Williamson, A. Kartheuser, J. Coaker, M. Kooshkghazi, R. Fodde et al., Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months, Carcinogenesis, vol.20, issue.5, pp.805-810, 1999.
DOI : 10.1093/carcin/20.5.805

M. Thun, S. Henley, and C. Patrono, Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues, JNCI Journal of the National Cancer Institute, vol.94, issue.4
DOI : 10.1093/jnci/94.4.252

T. Crew, D. Elder, and C. Paraskeva, A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate, Carcinogenesis, vol.21, issue.1, pp.69-77, 2000.
DOI : 10.1093/carcin/21.1.69

T. Menzel, J. Schauber, F. Kreth, T. Kudlich, R. Melcher et al., Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells, European Journal of Cancer Prevention, vol.11, issue.3, pp.271-281, 2002.
DOI : 10.1097/00008469-200206000-00011

J. Burn, P. Chapman, D. Bishop, and J. Mathers, Diet and cancer prevention: the Concerted Action Polyp Prevention (CAPP) Studies, Proceedings of the Nutrition Society, vol.270, issue.02, pp.183-186, 1998.
DOI : 10.1001/archinte.154.4.394